These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21570510)

  • 1. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials.
    Kotecha D; Ngo K; Walters JA; Manzano L; Palazzuoli A; Flather MD
    Am Heart J; 2011 May; 161(5):822-831.e2. PubMed ID: 21570510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients.
    Ngo K; Kotecha D; Walters JA; Manzano L; Palazzuoli A; van Veldhuisen DJ; Flather M
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007613. PubMed ID: 20091643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis.
    Tehrani F; Dhesi P; Daneshvar D; Phan A; Rafique A; Siegel RJ; Cercek B
    Cardiovasc Drugs Ther; 2009 Dec; 23(6):511-8. PubMed ID: 19862609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
    Kang J; Park J; Lee JM; Park JJ; Choi DJ
    Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
    J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
    Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure.
    Lindquist DE; Cruz JL; Brown JN
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):59-65. PubMed ID: 24996902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of erythropoietin in heart failure management.
    Caiola K; Cheng JW
    Ann Pharmacother; 2004 Dec; 38(12):2145-9. PubMed ID: 15494385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
    Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis.
    Zhang H; Zhang P; Zhang Y; Yan J; Dong P; Wang Y; Niu X
    Postepy Kardiol Interwencyjnej; 2016; 12(3):247-53. PubMed ID: 27625688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
    Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis.
    Desai A; Lewis E; Solomon S; McMurray JJ; Pfeffer M
    Eur J Heart Fail; 2010 Sep; 12(9):936-42. PubMed ID: 20525985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents.
    Johansen KL; Finkelstein FO; Revicki DA; Gitlin M; Evans C; Mayne TJ
    Am J Kidney Dis; 2010 Mar; 55(3):535-48. PubMed ID: 20133033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
    Ludwig H; Crawford J; Osterborg A; Vansteenkiste J; Henry DH; Fleishman A; Bridges K; Glaspy JA
    J Clin Oncol; 2009 Jun; 27(17):2838-47. PubMed ID: 19380447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoiesis-stimulating agents and heart failure.
    Lipšic E; van der Meer P; van Veldhuisen DJ
    Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.